HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elixir International

This article was originally published in The Rose Sheet

Executive Summary

A "200-page Vogue-style magazine" and "the first quarterly consumer glossy to target the huge interest in anti-aging products and services," Elixir International will launch in UK and internationally in October for $7, according to Aug. 24 announcement. Targeted to men and women over the age of 28, magazine will be distributed free to spas, cruise ships, luxury hotels, gyms, airport business lounges and private charter jets, and it will be available online to meet demand of Internet readers and advertisers, Elite Publishing of London notes. "If it's hot, new and will improve your lifespan ... you will find out about it" in Elixir International, publisher says. Coverage will encompass anti-aging cosmetics, nutraceuticals, cosmeceuticals, diet and exercise, cosmetic surgery, cosmetic dentistry and spas, but anti-aging lifestyle "may also be reflected by your home, its décor and even the type of car that you drive and the way you dress," Elite says. Magazine's medical panel includes Dr. Bob Goldman, chairman of the American Academy of Anti-Aging Medicine, cosmetic surgeon Javier de Benito and Dr. Nicholas Perricone, creator of skin-care brand PerriconeMD (1"The Rose Sheet" April 7, 2008, p. 8)

You may also be interested in...

PerriconeMD Overhauls Skin-Care Line For Independent, Informed Consumers

PerriconeMD Cosmeceuticals has repackaged and repositioned its skin-care line to cater to increasingly knowledgeable consumers and "improve both the purchase and user experience.

Hikma And Civica Ship Eight Essential Injectables

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

AstraZeneca's Calquence Steps Up in First-Line CLL

A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts